Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma.
Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5 degrees C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5 degrees C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.
Di Filippo
F
F
Regina Elena National Cancer Institute - Rome, Italy. difilippo@ifo.it
Cavaliere
F
F
Anzà
M
M
Garinei
R
R
Botti
C
C
Perri
P
P
Di Angelo
P
P
Patrizi
V
V
Di Filippo
S
S
Visca
P
P
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage*; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy*
D008081:Liposomes; D004317:Doxorubicin